More about

Sacituzumab Govitecan

News
December 20, 2022
3 min watch
Save

VIDEO: Sacituzumab govitecan effective regardless of Trop-2 expression level

VIDEO: Sacituzumab govitecan effective regardless of Trop-2 expression level

Results presented from TROPiCS-02 showed that sacituzumab govitecan was effective in a subset of patients with breast cancer regardless of Trop-2 expression level, according to data presented at San Antonio Breast Cancer Symposium.

News
October 26, 2022
7 min watch
Save

Important takeaways in breast cancer from ESMO 2022

Important takeaways in breast cancer from ESMO 2022

In this video, Erica L. Mayer, MD, MPH, discusses important takeaways from breast cancer sessions at this year’s European Society for Medical Oncology Congress.

News
October 12, 2022
1 min read
Save

FDA grants priority review to Trodelvy for pretreated metastatic breast cancer

FDA grants priority review to Trodelvy for pretreated metastatic breast cancer

The FDA granted priority review to sacituzumab govitecan-hziy for treatment of certain patients with advanced breast cancer.

News
July 07, 2022
2 min read
Save

Healio roundup: Top coverage in breast cancer from ASCO 2022

Healio rounded up the top breast cancer coverage presented and discussed at ASCO Annual Meeting in Chicago.

News
June 04, 2022
3 min read
Save

Sacituzumab govitecan significantly extends PFS in advanced breast cancer subset

Sacituzumab govitecan significantly extends PFS in advanced breast cancer subset

CHICAGO — Sacituzumab govitecan significantly extended PFS vs. single-agent chemotherapy among patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer, according to study results.

News
March 08, 2022
2 min read
Save

Trodelvy prolongs PFS in metastatic breast cancer subset, topline data show

Trodelvy prolongs PFS in metastatic breast cancer subset, topline data show

A phase 3 study of sacituzumab govitecan-hziy met its primary endpoint of PFS among a subset of patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to topline data released by the agent’s manufacturer.

News
April 13, 2021
1 min read
Save

FDA approves Trodelvy for advanced urothelial cancer

FDA approves Trodelvy for advanced urothelial cancer

The FDA today granted accelerated approval to sacituzumab govitecan for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor.

News
April 07, 2021
1 min read
Save

FDA grants regular approval to Trodelvy for triple-negative breast cancer

The FDA granted regular approval to sacituzumab govitecan for treatment of certain patients with triple-negative breast cancer.

News
December 11, 2020
4 min read
Save

Sacituzumab govitecan effective for triple-negative breast cancer regardless of biomarkers

Sacituzumab govitecan effective for triple-negative breast cancer regardless of biomarkers

Women with metastatic triple-negative breast cancer benefited from sacituzumab govitecan irrespective of their Trop-2 expression level and BRCA1/BRCA2 mutation status, according to data from the phase 3 ASCENT study.

News
October 27, 2020
9 min read
Save

Advances in treatments for genitourinary malignancies provide silver lining to 2020

Advances in treatments for genitourinary malignancies provide silver lining to 2020

This year has seen some groundbreaking advances in genitourinary oncology, particularly in the fields of prostate, kidney and urothelial cancers.

View more